Samsung Bioepis Co., Ltd. has signed a settlement and license agreement with Johnson & Johnson concerning the commercialization of PYZCHIVA®, a biosimilar to Stelara (ustekinumab)1, in Europe. The terms of the agreement remain confidential. Ustekinumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that prevents abnormal regulation of IL-12 and IL-23 associated with immune-mediated diseases. PYZCHIVA, developed by Samsung Bioepis, was approved as a biosimilar to Stelara (us...

The FIFA Global Citizen Education Fund (“the Fund”) is an important global initiative committed to expanding access to quality education and sports for children everywhere. Supported by MetLife Foundation, a founding donor, the Fund has opened for applications from nonprofit organizations focused on K-12 education. Applications for funding will be accepted through December 31, 2025. The Fund aims to expand access to quality education, literacy, and sport by providing grants to grassroots prog...

Algorithm, a pioneering regional pharmaceutical manufacturer has announced the signing of a strategic partnership agreement with Batterjee Pharma, a leading Saudi pharmaceutical company, becoming the first Lebanese company to localize its portfolio in the Kingdom. The agreement covers the manufacturing and supply of several EU & Japanese licensed Algorithm products. The collaboration will kick off with products targeting the treatment of critical therapeutic areas as hyperlipidemia, dysli...